newsfilter
← Latest News
Business Wire·

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

  • Zura Bio Limited appointed Muzammil Mustufa as Chief Business Officer (CBO) to oversee corporate strategy, business development, commercial planning, & investor relations.
  • Mustufa brings 20 years of pharmaceutical & biotechnology experience, including recent roles as VP of Corporate Strategy at Amicus Therapeutics & integration planning for Amicus's $4.8 billion acquisition by BioMarin Pharmaceutical Inc.
  • His prior career includes positions at GSK plc, The Frankel Group, & The D.E. Shaw Group.
  • CEO Sandeep Kulkarni stated Mustufa's addition complements the leadership team as the company approaches key clinical milestones for tibulizumab.
  • Mustufa highlighted tibulizumab as a first-in-class bispecific antibody blocking both IL-17 & BAFF pathways to treat serious immune system disorders.
  • Zura's lead candidate tibulizumab (ZB-106) is currently evaluated in two Phase 2 studies: TibuSHIELD for hidradenitis suppurativa (HS) & TibuSURE for systemic sclerosis (SSc).
  • Additional candidates torudokimab (ZB-880) & crebankitug (ZB-168) have completed Phase 1/1b studies & are being assessed for various autoimmune & inflammatory conditions.
  • The press release includes standard forward-looking statement disclaimers regarding risks, uncertainties, & potential deviations from projected clinical or financial outcomes.